Mycobacterium terrae infection can cause debilitating disease that is relatively resistant to antibiotic therapy. Two cases are presented, and data from an additional 52 reports from the literature are reviewed. Tenosynovitis of the upper extremity, often following trauma, was the most commonly reported presentation (59% of cases), with pulmonary disease occurring in an additional 26% of cases. Underlying medical problems were absent (44%) or not reported (28%) in 72% of the cases. One-half of the patients with upper extremity tenosynovitis were treated with local or systemic corticosteroids, before microbiological identification. Only onehalf of the patients with tenosynovitis who were followed up for 6 months had clinical improvement or were cured. The other one-half of the patients required repeated debridement, tendon extirpation, or amputation. The best antimicrobial therapy for M. terrae infection is unknown but might include a macrolide antibiotic plus ethambutol and one other effective drug for at least 12 months after clinical response. Parenteral treatment with an aminoglycoside and surgery may be useful in selected cases.
Despite the common opinion that M. terrae complex isolates are nonpathogenic [5] , these organisms are occasionally identified in the clinical laboratory in the setting of clinical disease of the joints, tendons, lung, gastrointestinal tract, and genitourinary tract. We describe 2 patients who presented to our hospitals with this unusual and challenging infectious disease and review data from other cases reported in the medical literature.
Case Reports

Case 1.
A 37-year-old woman, an elementary school teacher with no previous medical problems, presented with a small erythematous lesion at the tip of her right index finger in September 1996. She was advised to soak the finger. Two weeks later, she was diagnosed with osteoarthritis and was treated with anti-inflammatory medications. The lesion continued to extend proximally, and 3 months later, she consulted an orthopedic surgeon who recommended nonsteroidal antiinflammatory drug treatment and splinting. Five months later, she received a corticosteroid injection into the site. Her symptoms were relieved for 1 week but then recurred with increased swelling. She received a second corticosteroid injection, without symptomatic improvement.
The patient consulted a hand surgeon who did extensive debridement and tenosynovectomy in March 1997; culture of surgical specimens was performed. When culture yielded mycobacteria, the patient was treated empirically with rifampin and Figure 1 . Palmar surface of the right hand of a patient with Mycobacterium terrae infection (case 1). There is a recurring pus pocket at the base of the area of palmar wound dehiscence secondary to recurrent M. terrae infection.
ethambutol for 3 months, pending mycobacterial identification. Antimicrobial therapy was stopped when the isolate was identified as M. terrae, since the pathogenicity of the organism was uncertain. The patient continued to have drainage and decreased range of motion of her right hand. Therefore, on the basis of data from in vitro drug susceptibility testing, therapy with clarithromycin and ethambutol was started. Debridement was done again in September 1997. However, the surgical wound dehisced, and following repeated incision and drainage, a sinus tract formed that was associated with persistent, serosanguineous drainage (figure 1). M. terrae was isolated from the second surgical specimen, and the patient was referred for a second opinion on treatment.
On the basis of the results of in vitro drug susceptibility testing for the 2 M. terrae isolates, a 5-drug antibiotic regimen (clarithromycin, ciprofloxacin, ethambutol, ethionamide, and iv amikacin) was started in December 1997 in anticipation of a third surgical debridement. Review of the history revealed that the patient had maintained an aquarium containing tadpoles and had participated in plant-potting projects in her classroom during the months before the onset of her initial finger lesion. She did not recall any distinct trauma during these activities. She did not have fevers, fatigue, anorexia, regional adenopathy, respiratory or gastrointestinal symptoms, or weight changes during the course of this illness.
The patient had an episode of dysuria with sterile pyuria that was treated with a 10-day course of nitrofurantoin in September 1997. An iv pyelogram was unremarkable. Dysuria resolved, but sterile pyuria was noted again in December 1997. Although the 5-drug antimycobacterial regimen was being administered, fluorescent stains did not reveal acid-fast bacilli, and cultures of multiple first morning urine specimens were negative for acid-fast bacilli.
After extensive surgical debridement (5 surgeries, most recently in May 1998) and prolonged, multidrug antibiotic therapy (ending 31 December 1998), the patient was free of disease. There was no evidence of inflammation or drainage at the last follow-up in August 1999. To rule out osteomyelitis, MRI was performed in July 1998 (which was negative), and triple-phase bone scanning was performed in December 1998 (which was also negative). She adroitly compensates for lost function of the right index finger by using her third digit. She wears a jeweled finger splint and has intact sensation. She has resumed teaching and calligraphy.
Case 2. A 42-year-old woman presented to her primary care physician in April 1995 with right index finger pain and swelling. She reported a strain injury to her right index finger that occurred while she was repairing a garden fence; however, she indicated that she was wearing gloves and could not recall any puncture wound. Her medical history and system review were otherwise negative. Because of continued pain and swelling, the patient was treated with several local corticosteroid injections. Pathological studies following synovectomy, which was performed in November 1995, showed "granulomatous tenosynovitis." Cultures of surgical specimens yielded M. terrae. The patient was afebrile; no regional adenopathy, pulmonary findings, or other physical examination findings, other than those for her hand, were noted. There was flexion contracture of the right index finger and a small fluid collection at its base.
Postoperatively, the patient was treated with clarithromycin for 5 months, after which time rifampin was added to the treatment because of minimal clinical improvement during clarithromycin monotherapy. In April 1996, debridement was done again, and cultures of the surgical specimen were negative for common bacteria, mycobacteria, and fungi. Special stains did not reveal any organisms, and pathological studies again revealed caseating granulomas (figure 2). After the second debridement, on the basis of results of in vitro drug susceptibility testing, ciprofloxacin and ethambutol were added to clarith- romycin and rifampin therapy. However, rifampin therapy was stopped in July 1996 because of chemical hepatitis, and clarithromycin treatment was stopped in October 1996 because of nausea and headache.
Despite the continued use of ciprofloxacin and ethambutol and the periodic empirical use of other antibiotics, the infection progressed. MRI of the right hand in December 1996 showed inflammation of the tendons of the second musculus flexor digitorum profundus and musculus flexor digitorum superficialis. On 30 December 1996, the patient underwent right index finger amputation (ray procedure). Pathological examination of tissue sections from the amputated finger revealed necrotizing granulomatous inflammation of the flexor tendon and no osteomyelitis. Antibiotic therapy was continued for 6 months after amputation. There was no recurrence of infection 18 months after amputation.
Literature Review
Case reports from the world literature were reviewed to better understand the clinical experience with M. terrae disease. Details from 52 cases of this disease and the 2 cases reported here are shown in table 1. Because the methods for identifying members of the M. terrae complex have changed in the years since the first case report [2, 3] , many reports in this series did not include sufficient biochemical data to verify the taxonomic status of the organisms according to current standards. Species identification by use of high-performance liquid chromatography (HPLC) analysis of mycolic acid patterns was done only in a few cases.
In the 54 cases (table 1), the ages of the patients ranged from 6 months to 75 years (median age, 50 years). There were 32 males, and 21 females; gender was not reported for 1 patient. The duration of symptoms until microbiological identification ranged from 3 weeks to 6 years, but usually 16 months elapsed before M. terrae was established as the etiologic agent. Cases were reported from diverse parts of the world, mostly temperate climates including the United States (29 cases), Japan (10), Sweden (7), Netherlands (2), France (2), England (1), Argentina (1), Australia (1), and Hong Kong (1) . The locations where these cases were reported, however, could reflect the availability of laboratory services rather than the regional incidence of M. terrae infection.
Most patients (24 [62%] of 39) whose underlying or comorbid conditions were reported had no predisposing conditions and were thought to be immunologically intact. Of the few patients with a reported underlying disorder, 3 had diabetes mellitus, 2 had a history of malignancy, and 9 had other miscellaneous disorders, including rheumatoid arthritis, renal transplant, prior surgery, AIDS, and alcoholism.
The most frequently infected sites in the 54 case patients were the upper extremities, including the arm, wrist, hand, or fingers in 32 cases (59%). Other sites of infection included the lung in 14 patients (26%), bone other than the hand (hip, knee, or ankle) in 4 (7%), and genitourinary or gastrointestinal sites in 3 (6%). Of the subset of 32 patients who had infection in the upper extremity, including the wrist, hand, or fingers, 17 (53%) were treated with corticosteroids (either injected locally in 12 [38%] or given systemically in 5 [16%]) before the diagnosis of infection was made. Reported outcomes for 31 patients with tenosynovitis in the upper extremity showed that only 22 (71%) were cured or had improvement in their conditions, whereas 9 (29%) had persistent disease that resulted in repeated debridement, tendon extirpation, or amputation.
A review of the antibiotic treatment regimens used for the 54 patients showed that most patients (45 [83%]) were treated with multiple antibiotics. Five of the 54 patients received no antibiotic therapy, and 2 patients were treated with a single antibiotic. Of the 5 patients with untreated M. terrae infections, 2 died of pulmonary disease, 2 had recurrent or persistent infection of the wrist, and 1 had a finger infection that improved. The 2 patients treated with a single antibiotic received either doxycycline or erythromycin; 1 patient's condition was improved after 3 months of follow-up, and the other patient was cured after 24 months of follow-up. When we divided patients treated with multidrug regimens into those with positive outcomes (improvement or cure) or and those with negative outcomes (persistence, recurrence, amputation, or death), there was no single antibiotic or combination of antibiotics whose use was significantly associated with a positive result of therapy (table 2) . There was a trend toward an improved outcome for patients treated with regimens containing both rifampin and ethambutol that did not reach statistical significance ( ). However, the suggested benefit P = .09 could be related partly to the fact that these 2 drugs were used for the largest number of patients (45 [83%] of 54). Small numbers of patients (1-6) were treated with antibiotic regimens containing other drugs or drug combinations not listed in tables 3 and 4. These included the following: ethionamide (2 patients), macrolides (6), p-aminosalicylic acid (2), pyrazinamide (4), fluoroquinolones (5), rifabutin (1), sulfonamides (5), and tetracyclines (6). It was not possible to assess the correlations between the uses of these drugs and clinical outcomes because of the small number of cases.
Antibiotic Susceptibility Testing
Because of the paucity of data from in vitro antibiotic susceptibility testing, empirical treatment of M. terrae infections has not been established. To obtain initial information to assist in these clinical decisions, isolates of M. terrae were tested for antibiotic susceptibility in 2 types of in vitro assays. These clinical isolates were from specimens referred to the Mycobacteriology Laboratory at the National Jewish Hospital (Denver, CO) during the 4-year period from October 1993 to September 1997. Eight of the specimens were isolated from sputum, and 7 were isolated from upper extremity infections. All isolates were identified as M. terrae by morphology and conventional biochemical studies, and identification to the species level for most isolates was confirmed by HPLC analysis of mycolic acid patterns.
Fifteen M. terrae isolates were tested by the agar plate proportion method commonly used to test drug susceptibility of Mycobacterium tuberculosis and most nontuberculous mycobacteria (table 3) . Ethambutol was the most active drug in this assay (93% susceptible). By contrast, isoniazid and p-aminosalicylic acid were inactive.
MICs of several drugs were determined for a variable number of M. terrae isolates (table 4). All isolates were susceptible to the semisynthetic macrolide antibiotics azithromycin and clarithromycin, with MICs less than or equal to the lowest concentration tested. As was observed by the agar plate proportion method, most (86%) of the isolates were also susceptible to ethambutol (MIC, р2 mg/mL). Approximately one-half of the isolates were susceptible to the aminoglycoside antibiotics amikacin and streptomycin. As was observed by the agar plate proportion method for rifampin, only 20%-25% of isolates were susceptible to the rifamycin antibiotics rifampin and rifabutin. Only 1 isolate was susceptible to either ciprofloxacin or clofazimine.
Discussion
The reported cases listed in table 1 probably represent a small fraction of actual cases of M. terrae disease, since we have noted almost this many cases from data at our institutions alone in recent years. For example, a review of records indicated that there were at least 7 cases of M. terrae infection in the last 12 years at Stanford University Medical Center. Furthermore, at least 16 different referral cultures of M. terrae were recorded at the Mycobacteriology Laboratory, National Jewish Hospital, over the 4-year period from 1993 to 1997.
This review indicates that infection with M. terrae can result in debilitating disease, most commonly tenosynovitis of the hand. Comparison of the reported sites of infection with the exposures and occupations or hobbies of patients suggests the importance of trauma in this infection (table 1) . Thirty-two (59%) of 54 of these patients had infections of the upper extremity. In 19 (59%) of these 32 patients, there was either a history of an antecedent puncture wound of the hand (9 patients) or an occupation or hobby that could have exposed the patient to an increased risk of hand trauma and wound contamination, such as farming (4 patients), gardening (3 patients), fish tank maintainance, butchering, and cooking professionally (1 patient each). The second most common site of infection was the lung (14 [26%] of 54 patients). Pulmonary infection with M. terrae can result in a cavitary process, and caseating granulomas are observed if pathological analysis is performed. Insufficient information was provided in these case reports to allow speculation about environmental exposures that might have resulted in pulmonary infection.
The long interval between the onset of symptoms and the microbiological identification of M. terrae, and the initial use of corticosteroid therapy in these cases, suggest that the clinical presentation was often nonspecific and that a noninfectious inflammatory condition was suspected initially in most cases (table 1) . Of the 43 cases in which the interval between the onset of symptoms and the identification of the etiologic agent was reported, the mean was months. The time ‫ע‬ SD 12.6 ‫ע‬ 16 range of this interval was wide, varying from diagnosis at presentation to a lag period of 6 years. However, the diagnosis of M. terrae infection required at least 6 months in more than one-half (23) of the 43 cases. Corticosteroid therapy before diagnosis of M. terrae infection was discussed in 26 of the 32 case patients who had signs and symptoms in the upper extremities (finger, 19 patients; wrist, 4; arm, 2; and hand, 1). More than one-half (15 [58%]) of these 26 patients were treated with corticosteroids. The morbidity associated with delayed diagnosis and the possible adverse effects of corticosteroid therapy in untreated chronic infections underscore the importance of including M. terrae infection (and other occult infections) in the differential diagnosis of refractory tenosynovitis that is thought to be of a nonspecific inflammatory nature.
The morbidity and mortality associated with M. terrae infections are probably a reflection of the inadequacy of antibiotic regimens than of insufficient host defenses associated with underlying medical conditions. Of the 29 patients with M. terrae infection of the finger, wrist, or hand for whom treatment outcome was reported, 6 (21%) had infection described as persistent or recurrent, and 3 (10%) eventually underwent ampu- (94) 16 NOTE. Four strains were tested with doxycycline, and 1 was tested with minocycline; all were resistant. Three strains were tested with ofloxacin, and all were resistant. Three strains were tested with cycloserine, and all were resistant. One strain was tested with augmentin and was susceptible.
tation (table 1) . There was no correlation between the presence of a comorbid condition and an undesirable outcome in these cases. Thus, despite the absence of a reported underlying illness, 31% of patients with hand infections had persistent or recurrent disease, and 2 of the 3 reported amputations were performed for patients who had no underlying medical problem. Similarly, the outcomes for 6 (43%) of the 14 patients with M. terrae pulmonary infections were negative. Of these 6 patients, 4 (29%) died and 2 (14%) had persistent infection. Only 1 of 6 patients had a reported underlying medical problem (a bone marrow transplant patient who died of M. terrae infection).
A review of these case reports suggests the possibility that multidrug regimens containing rifampin and ethambutol might be associated with improvement or cure of M. terrae infections (table 2) . This possibility is consistent with the finding that ethambutol was effective in vitro against most of the M. terrae isolates tested (tables 3 and 4). Whether there is an additive or synergistic effect of the combination of rifampin and ethambutol that could be detected in vitro is unknown.
Most of these case reports were from a period before the common use of fluoroquinolone and semisynthetic macrolide antibiotics. Therefore, these observations do not address the question of whether clinical outcomes could be improved by the use of these newer agents in treatment regimens. Our in vitro MIC data suggest that macrolide antibiotics (azithromycin and clarithromycin), which were effective against 100% of the M. terrae isolates tested, might be preferable empirical choices over quinolones (e.g., ciprofloxacin), pending the results of antibiotic susceptibility testing for a clinical isolate (table 4) .
Because it is unlikely that a controlled study of the treatment of deep-seated M. terrae infections will be possible in the near future, it is useful to consider the limited recommendations that can be derived from these case reports and in vitro antibiotic susceptibility studies. The most important recommendation suggested by this review is that M. terrae infection (and infections due to other nontuberculous mycobacteria) should be considered in the differential diagnosis for all patients who have localized tenosynovitis and a history of hand trauma with possible soil or water contamination for whom a common bacterial pathogen cannot be isolated from affected tissue. A history of occupational or recreational exposure to soil at sites of trauma should be sought in patients with chronic tenosynovitis, and, if this history is elicited, chronic infection with M. terrae and other low-grade pathogens should be explicitly excluded before corticosteroid therapy is administered. Entertaining the possibility of an indolent mycobacterial infection in such cases might reduce the inappropriate use of corticosteroid therapy in the context of unsuspected infection.
The differential diagnosis for a patient with chronic infectious tenosynovitis includes infections with a variety of pathogens. If there is no known inciting injury, it may be difficult to distinguish the first presentation of a chronic mycobacterial infection from tenosynovitis or septic arthritis due to another cause. Acute purulent infections can be caused by several conventional pathogens. Gram-negative aerobic bacteria, such as might be expected in farm injuries where fecal matter may have been inoculated, can cause tenosynovitis. Infections with anaerobes such as Clostridium tetani or Clostridium perfringens can occur after hand injury involving soil. Staphylococcus aureus and Streptococcus species are common skin flora with the potential to infect tendons or synovial tissue if a puncture wound occurs. All of these infections would be expected to be associated with a more acute presentation than is suggested by the case reports of M. terrae-induced tenosynovitis.
Hematogenous spread of Neisseria gonorrhoeae can also affect a single small digit or upper extremity joint, although infections with this bacterium more commonly involve larger joints. Herpes simplex (herpetic whitlow) must also be considered in the differential diagnosis of chronically suppurative hand or finger wounds where bacterial pathogens cannot be isolated. For more indolent cases of tenosynovitis, infections with other mycobacteria or fungi should be considered, in addition to the less common possibility of M. terrae infection. Considering the difficulty in the diagnosis of M. terrae tenosynovitis (as evidenced by the long latent period before diagnosis of infection in most cases; table 1), it is appropriate to submit all tissue specimens from related surgeries for acid-fast staining and culture, as well as for routine pathological examination. This diversity of diagnostic possibilities for patients with tenosynovitis underscores the importance of aggressively seeking the specific microbiological identification in all such cases.
Pending final results of antibiotic susceptibility testing, an empirical drug treatment regimen for M. terrae infection could include clarithromycin, rifampin, and ethambutol. This suggestion is based on our synthesis of data from these case reports (table 2) , results of the in vitro susceptibility testing (tables 3 and 4), and our experience treating infections due to other nontuberculous mycobacteria. Considering the difficulty that we and others have had in eradicating M. terrae infections in patients with tenosynovitis, it would be reasonable to extend the duration of therapy to at least 12 months after an initial clinical response.
M. terrae organisms are much less common mycobacterial pathogens than are other nontuberculous mycobacteria at any site of infection. The design of an empirical antibiotic regimen after isolation of mycobacteria from a normally sterile site should account for this extended spectrum of pathogens, until final identification and antibiotic susceptibility testing are completed. Fortunately, it appears that from the drug susceptibility patterns presented in tables 3 and 4 and from the review of the clinical outcomes in cases from the literature (table 2) , an empirical regimen of a macrolide antibiotic (e.g., clarithromycin), ethambutol, and rifampin would be a reasonable initial choice for treatment of M. terrae infections. On the basis of our experience, this is also a reasonable empirical regimen for treatment of infections due to other nontuberculous mycobacteria. Macrolides should not be used as single agents in this setting, because of the possible emergence of antibiotic-resistant mycobacterial populations following monotherapy. The possible value of adding an aminoglycoside antibiotic (e.g., amikacin) to the initial regimen depends on the urgency of the clinical situation and the relative risk-benefit ratio in the specific case. The susceptibility of M. terrae isolates to antibiotics other than the macrolides and ethambutol appears to be variable (tables 3 and 4). Therefore, until further clinical data are available, it is reasonable to test all clinical M. terrae isolates for drug susceptibility in vitro to aid in the selection of additional drugs. Although we advocate the use of antibiotic susceptibility testing in cases of infection due to nontuberculous mycobacteria, we also acknowledge that experimental evidence for basing the design of a treatment regimen on data from antibiotic susceptibility testing is limited.
Until more effective antibiotics are identified for treatment of M. terrae infections, it will be necessary to consider, on a case-by-case basis, the value of combined medical-surgical therapy for patients with localized disease. Debridement or resection of relatively avascular tissue, such as soft-tissue sites of the hand and destroyed lung segments or lobes, may be an important adjunct to marginally effective multidrug regimens. Even if the M. terrae isolate appears to be susceptible to drugs in vitro, adequate antibiotic concentrations may not be achieved in such sites. The use of aminoglycoside beads (i.e., amikacin) in bone and joint infections to achieve higher local drug concentrations and to avoid systemic toxicity is conceptually attractive. However, these preparations are often not well standardized, and their use may be limited by the small sizes of tissue spaces involved and wound closure constraints (e.g., in hand surgery). With the addition of macrolide antibiotics for the treatment of M. terrae tenosynovitis, it is hoped that amputation should be needed only rarely, if at all.
This review suggests that M. terrae infection is a relatively uncommon problem that can be mistaken for a noninfectious inflammatory joint process. Formal exclusion of a mycobacterial infection or other chronic infectious etiologies might avoid undesirable consequences of corticosteroid therapy in patients with M. terrae infection. A multidrug antibiotic regimen, including a macrolide, and consideration of the role of surgical debridement are useful initial approaches to the management of such patients. In vitro antibiotic susceptibility testing for the mycobacterial isolate might be useful to refine therapy, which may have to be continued for a prolonged period to increase the possibility of cure.
